Comparing Golqand (Persian Medicine Product) with Magnesium Hydroxide in Adult Constipation: A Randomized Clinical Trial

Sayeh Ghorbanoghli; Seyyed Ali Mozaffarpoor; Mohammad Ali Vakili; Taghi Amiriani; Marzieh Qaraaty

doi:10.18502/tim.v6i4.8268

Sayeh Ghorbanoghli Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Seyyed Ali Mozaffarpoor Traditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
Mohammad Ali Vakili Health Management and Social Development Research Center, Department of Biostatistics and Epidemiology, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
Taghi Amiriani Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
Marzieh Qaraaty Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran

DOI: https://doi.org/10.18502/tim.v6i4.8268

Keywords: Rosa × damascena Herrm.; Laxatives; Herbal; Constipation; Persian medicine

Abstract

Chronic constipation is a highly prevalent digestive problem in the community, which would decrease the quality of life of individuals. There is not any conclusive drug of choice for constipation. Golqand (combined Rosa × damascena Herrm. and honey) has been introduced as an effective safe laxative in Persian medicine (PM). This study aimed to investigate the effects of Golqand in comparison with Magnesium hydroxide suspension (MOM) in chronic constipation. In this clinical trial, fifty-six patients with chronic constipation were randomly assigned to the study groups of Golqand or MOM. Patients received Golqand (20 g daily) or MOM (40 mL daily) for 2 weeks. Patients took the drug twice a day, MOM group used it in the morning (20 mL) and at night before going to bed (20 mL). The Golqand group used it 10 g before lunch and 10 g before dinner, dissolved it in lukewarm water and swallowed. Then, they were followed for the second two weeks without any medication. The primary outcome was frequency of defecation. Patients were evaluated before the study and two weeks and four weeks after the beginning study. Estimated marginal mean frequency of defecation in the MOM group in the first two weeks was significantly higher than the Golqnd group (P < 0.05). There was no significant difference among the groups in the third week when treatment was discontinued (P = 0.155) but in the fourth week, the Golqand group had more count of defecation than the MOM group (P = 0.001). There was no significant difference between the two study groups in terms of treatment satisfaction and drug side effects (P > 0.05). Golqand medication can be used in the treatment of constipation with very few drug side effects and a more lasting effect than MOM drug.